- SID Score
- 6.8/10
- Fair value
- $509.31
- Generated
- Sep 10, 2026
- Model
- claude-haiku-4-5-20251001
Bristol-Myers Squibb's Preferred Convertible 2 (BMYMP) is trading at $400.00 with a significant market capitalization of $1.82 trillion, reflecting the company's substantial position in the healthcare sector. The security presents a fair value estimate of $509.31, suggesting approximately 27.3% upside potential for investors. With an analyst consensus rating of "Buy" and a moderate SID Score of 6.8/10, BMYMP appears positioned as a moderately attractive investment opportunity, though investors should carefully evaluate its specific characteristics as a convertible preferred security.
The valuation metrics indicate a P/E ratio of 17.28, which is reasonable within the healthcare sector context, though the low dividend yield of 0.05% suggests limited income generation from this particular security. Factor grades reveal mixed fundamentals with profitability and growth both rated at "C," while the value factor receives a concerning "D" grade, indicating potential overvaluation relative to intrinsic worth. The absence of recent annual financials and earnings data limits deeper fundamental assessment, making it challenging to evaluate the underlying company's financial health and performance trajectory.
Technical analysis cannot be meaningfully performed on BMYMP due to the unavailability of key indicators including RSI(14), 50-day moving average, and 200-day moving average data. Without these essential technical metrics, investors cannot assess current momentum, trend direction, or potential support and resistance levels. This data limitation significantly restricts the ability to time entry and exit points or identify short-term trading opportunities.
Analyst & Insider Sentiment
Recent insider activity reveals concerning patterns with short seller Bartie Wendy executing multiple transactions on June 3, 2026, including sales of 8,040 and 12,081 shares alongside a smaller purchase of 15,957 shares, suggesting mixed confidence. Adam Lenkowsky also liquidated positions by selling 1,375 and 20,305 shares on May 1, 2026, indicating insider selling pressure despite the "Buy" analyst consensus. These insider transactions suggest potential skepticism about near-term appreciation prospects, creating tension with the overall analyst recommendation.
The primary risk stems from BMYMP's status as a convertible preferred security, which carries both equity and fixed-income risks alongside conversion timing uncertainty that could impact returns. The significant insider selling activity raises concerns about management confidence in the security's valuation and future performance, particularly with multiple consecutive sell transactions. Additionally, the lack of available financial data and technical indicators prevents comprehensive risk evaluation and increases uncertainty for prospective investors.
BMYMP presents a moderate buy opportunity for risk-tolerant investors given the 27.3% upside to fair value and "Buy" consensus rating, though the investment requires careful consideration of convertible-specific dynamics. The mixed fundamental grades (particularly the "D" value rating) and concerning insider selling activity suggest investors should wait for better entry points or demand additional information before committing capital. Conservative investors should exercise caution given the limited data availability and insider skepticism, whereas those comfortable with convertible securities and willing to accept conversion risk may find value at current levels.
